Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 835

1.

New Potassium Binders for the Treatment of Hyperkalemia: Current Data and Opportunities for the Future.

Pitt B, Bakris GL.

Hypertension. 2015 Aug 24. pii: HYPERTENSIONAHA.115.04889. [Epub ahead of print] No abstract available.

PMID:
26303290
2.

Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials.

Smith SA, Mentz R, Roessig L, Mebazza A, Longrois D, Gheorghiade M, Pitt B, Zannad F, Butler J, Abraham WT.

Am J Cardiol. 2015 Jul 29. pii: S0002-9149(15)01709-9. doi: 10.1016/j.amjcard.2015.07.049. [Epub ahead of print] Review.

PMID:
26282727
3.

Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies.

Vaduganathan M, Butler J, Pitt B, Gheorghiade M.

Circ Heart Fail. 2015 Jul;8(4):826-31. doi: 10.1161/CIRCHEARTFAILURE.115.002271. No abstract available.

PMID:
26199309
4.

Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.

Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators.

JAMA. 2015 Jul 14;314(2):151-61. doi: 10.1001/jama.2015.7446. Erratum in: JAMA. 2015 Aug 18;314(7):731. Dosage error in article text.

PMID:
26172895
5.

Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).

Cannon JA, Collier TJ, Shen L, Swedberg K, Krum H, Van Veldhuisen DJ, Vincent J, Pocock SJ, Pitt B, Zannad F, McMurray JJ.

Eur J Heart Fail. 2015 Jul;17(7):707-16. doi: 10.1002/ejhf.303.

PMID:
26139584
6.

Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.

Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD.

Circulation. 2015 Aug 4;132(5):402-14. doi: 10.1161/CIRCULATIONAHA.115.015884. Epub 2015 Jun 30.

PMID:
26130119
7.

Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.

Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, Van Veldhuisen DJ, Vincent J, Pitt B, Zannad F.

Eur Heart J. 2015 Jun 20. pii: ehv273. [Epub ahead of print]

PMID:
26093641
8.

Perinatal outcomes and unconventional natural gas operations in Southwest Pennsylvania.

Stacy SL, Brink LL, Larkin JC, Sadovsky Y, Goldstein BD, Pitt BR, Talbott EO.

PLoS One. 2015 Jun 3;10(6):e0126425. doi: 10.1371/journal.pone.0126425. eCollection 2015.

9.

Patient selection in heart failure with preserved ejection fraction clinical trials.

Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, O'Connor CM, Lam CS.

J Am Coll Cardiol. 2015 Apr 28;65(16):1668-82. doi: 10.1016/j.jacc.2015.03.043. Review.

PMID:
25908073
10.

Cardiovascular drug development: is it dead or just hibernating?

Fordyce CB, Roe MT, Ahmad T, Libby P, Borer JS, Hiatt WR, Bristow MR, Packer M, Wasserman SM, Braunstein N, Pitt B, DeMets DL, Cooper-Arnold K, Armstrong PW, Berkowitz SD, Scott R, Prats J, Galis ZS, Stockbridge N, Peterson ED, Califf RM.

J Am Coll Cardiol. 2015 Apr 21;65(15):1567-82. doi: 10.1016/j.jacc.2015.03.016. Review.

PMID:
25881939
11.

New agents for hyperkalemia.

Weir MR, Bakris GL, Pitt B.

N Engl J Med. 2015 Apr 16;372(16):1570-1. doi: 10.1056/NEJMc1501933. No abstract available.

12.

A reappraisal of loop diuretic choice in heart failure patients.

Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM.

Am Heart J. 2015 Mar;169(3):323-33. doi: 10.1016/j.ahj.2014.12.009. Epub 2015 Jan 6. Review.

PMID:
25728721
13.

Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators.

Butler J, Fonarow GC, O'Connor C, Adams K, Bonow RO, Cody RJ, Collins SP, Dunnmon P, Dinh W, Fiuzat M, Georgiopoulou VV, Grant S, Kim SY, Kupfer S, Lefkowitz M, Mentz RJ, Misselwitz F, Pitt B, Roessig L, Schelbert E, Shah M, Solomon S, Stockbridge N, Yancy C, Gheorghiade M.

Am Heart J. 2015 Mar;169(3):305-14. doi: 10.1016/j.ahj.2014.12.001. Epub 2014 Dec 17.

PMID:
25728719
14.

Emerging cardiovascular indications of mineralocorticoid receptor antagonists.

Parviz Y, Iqbal J, Pitt B, Adlam D, Al-Mohammad A, Zannad F.

Trends Endocrinol Metab. 2015 Apr;26(4):201-11. doi: 10.1016/j.tem.2015.01.007. Epub 2015 Feb 20. Review.

PMID:
25707577
15.

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.

Pitt B, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Nowack C, Kim SY, Pieper A, Kimmeskamp-Kirschbaum N, Filippatos G.

Eur J Heart Fail. 2015 Feb;17(2):224-32. doi: 10.1002/ejhf.218.

PMID:
25678098
16.

My approach to patients with heart failure and a normal ejection fraction.

Pitt B.

Trends Cardiovasc Med. 2015 Feb;25(2):164-5. doi: 10.1016/j.tcm.2014.07.009. Epub 2014 Oct 8. No abstract available.

PMID:
25592236
17.

The electromyographic threshold in boys and men.

Pitt B, Dotan R, Millar J, Long D, Tokuno C, O'Brien T, Falk B.

Eur J Appl Physiol. 2015 Jun;115(6):1273-81. doi: 10.1007/s00421-015-3100-5. Epub 2015 Jan 15.

PMID:
25588894
18.

Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.

Rossignol P, Zannad F, Pitt B; Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France.

Int J Cardiol. 2014 Dec 20;177(3):731-3. doi: 10.1016/j.ijcard.2014.11.004. Epub 2014 Nov 5.

PMID:
25465821
19.

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction.

Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM.

J Am Coll Cardiol. 2014 Dec 2;64(21):2281-93. doi: 10.1016/j.jacc.2014.08.036. Epub 2014 Nov 24. Review.

PMID:
25456761
20.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators.

N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk